<DOC>
	<DOCNO>NCT01866098</DOCNO>
	<brief_summary>This study design look effect naltrexone weight loss individual treat antipsychotic medication . Naltrexone FDA approve medication management alcohol dependence drug dependence , fully evaluate effect weight loss individual severe mental illness ( i.e . schizophrenia , schizoaffective disorder , bipolar disorder etc . ) The purpose study find effective two different dos oral naltrexone reduce body weight compare placebo ( inactive substance `` sugar pill '' ) .</brief_summary>
	<brief_title>Naltrexone Antipsychotic-Induced Weight Gain</brief_title>
	<detailed_description>Persons severe mental illness ( SMI ) die , average , 25 year earlier general population1 . Most early mortality attribute cardiovascular disease ( CVD ) diabetes mellitus ( DM ) , directly relate obesity . Obesity lead cause preventable death United States , second smoking . The physical health patient become major focus schizophrenia care , recent decade see immense gain symptom control community integration . There urgent need development intervention address obesity crisis schizophrenia . Patients treat antipsychotic medication show preference diet high fat sugar . Patients schizophrenia typically seek behavior increase dopamine mediate reward brain smoking substance use , occur often group general population . The system might require intact dopamine opioid function . Naltrexone oral agent competitively antagonize know opioid receptor brain . Human study naltrexone complete individual different illness , include schizophrenia , show safe easy agent use . It show decrease crave alcoholic approve FDA treatment alcohol dependence . Naltrexone report decrease craving substance abuse , like nicotine . Furthermore , show prevent secondary weight gain due cessation cigarette smoking low ( 25mg 50 mg ) , high dos . Naltrexone test human feeding study , show reduce quantity food eaten choice palatable food . Subjects randomize either 25 , 50 0mg Naltrexone take study medication daily 52 week . Subjects see weekly first 4 week study , thereafter see bi-weekly ( every week ) basis assess ( i.e . weight , side effect check , paper questionnaire ) throughout remain 48 week treatment . The purpose study determine efficacy two dos naltrexone ( 25mg &amp; 50mg ) versus placebo weight health risk reduction 144 obese individual severe mental illness treat antipsychotic medication .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Weight Gain</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Age 18 75 Meet Diagnostic &amp; Statistical Manual 4 ( DSMIV ) criterion schizophrenia , schizoaffective disorder , bipolar disorder , major depression , another psychotic disorder base Structured Clinical Interview DSMIV ( SCID ) interview Body Mass Index ( BMI ) 28 On stable dose antipsychotic medication ; i.e . least one month dose change , three month antipsychotic switch Deemed symptomatically stable clinical staff last two month Over 7 % total body weight increase antipsychotic subject within first year illness Meet criterion current opiate abuse dependence ( confirm positive urine drug screen opiate , suspect study doctor via patient history suspicion occult opiate use , naloxone challenge perform . ) Current history dementia , mental retardation Not capable give informed consent participation study Women pregnant breastfeed Physical condition affect body weight ( e.g . Cushing 's disease , polycystic ovary syndrome ) Diabetes Mellitus ( define prescribe antidiabetic medication diabetes hemoglobin A1c level &gt; 7 confirm primary care physician screening ) Severe liver dysfunction , ( serum aminotransferases great three time normal ) , acute infectious hepatitis , liver failure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>antipsychotic</keyword>
	<keyword>severe mental illness</keyword>
	<keyword>weight loss</keyword>
</DOC>